Stock EBAC EURO BIOT
Add to a list
To use this feature you must be a member
Log inSign up

News EURO BIOT

Equities

EBAC

KYG3167F1028

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
11.7 USD 0.00% Intraday chart for EURO BIOT -0.85% +4.56%
2023 European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index CI
2023 Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index
CI
Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.
CI
EUROPEAN BIOTECH ACQUISITION CORP. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
European Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
EUROPEAN BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt
CI
EUROPEAN BIOTECH ACQUISITION CORP. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
AQ
EUROPEAN BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
EUROPEAN BIOTECH ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
EUROPEAN BIOTECH ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
European Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
European Biotech Acquisition, Oculis Strike Merger Agreement
MT
European Biotech Acquisition : Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology - Form 8-K
PU
EUROPEAN BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Oculis SA entered into a Business Combination Agreement to acquire European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. in a reverse merger for approximately $210 million.
CI
EUROPEAN BIOTECH ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
European Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
EUROPEAN BIOTECH ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
European Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
EUROPEAN BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EBAC Stock
  4. News EURO BIOT